Matinas BioPharma Holdings, Inc.

Healthcare · Biotechnology · United States

Last price 1.51 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.48M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as preventi...